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Epidermal growth factor receptor (EGFR) is a prototypic cell-surface receptor belonging
to the ErbB/HER onocogene family. Overexpression or somatic mutations of EGFR
have been reported to play an important role in tumorigenesis in various types of
epithelial cancers. Therefore, targeting of EGFR with specific blocking antibodies or
inhibitors have been developing for treatment for EGFR-associated tumors. Immune
responses to HER2, another molecule of the ErbB/HER onocogene family, have been
well studied, but only limited information on the immune responses to EGFR in cancer
has been currently available. In this review, we have summarized the available data
and discussed potential clinical importance of the anti-EGFR immune responses and
EGFR-mediated immune regulation in cancer. Several lines of evidence suggest that
cellular and humoral immune responses to EGFR might be useful as a marker and/or
target for cancer therapy against EGFR-associated tumors. In addition, recent studies
suggest the critical roles of EGFR-mediated signaling in regulation of expression of
an immune checkpoint molecule, programmed death-ligand 1 (PD-L1) in tumor cells.
Further studies are warranted to clarify the impact of the anti-EGFR immune responses
and EGFR-mediated immunomodulation for clinical application for cancer treatment.
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INTRODUCTION
Epidermal growth factor receptor (EGFR), a prototypic cell-surface receptor belonging to the
ErbB/HER onocogene family, has been known to play an important role in the regulation of cell
proliferation, differentiation, and migration (Baselga and Arteaga, 2005; Tebbutt et al., 2013). In
addition, oncogenic somatic mutations in specific sites of the EGFR gene, such as EGFR variant
III (EGFRvIII) in glioblastoma multiforme (GBM) and activating EGFR mutations in non-small
cell lung cancer (NSCLC), have been reported to be closely associated with tumorigenesis (Guo
et al., 2015; Tan et al., 2015). Since EGFR is overexpressed in various types of epithelial cancers,
including pancreatic, colorectal, breast, and lung cancer, it has been suggested that EGFR might
be an appropriate target for cancer therapy. Indeed, EGFR-associated tumors have been targeted
by specific blocking antibodies or inhibitors for cancer treatment. In addition, personalized cancer
treatments targeting the oncogenic EGFR mutations are currently developing.
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Immune responses to HER2, another molecule of the
ErbB/HER onocogene family, have been well studied (Chapman
et al., 2008; Knutson et al., 2016; Tabuchi et al., 2016), but only
limited information on the immune responses to EGFR in cancer
has been currently available. We have been studying cellular and
humoral immune responses specific to EGFR (Yamada et al.,
2013; Azuma et al., 2014a), as well as modulatory effect of EGFR-
mediated signaling in expression of an immune checkpoint
molecule, programmed death-ligand 1 (PD-L1) (Azuma et al.,
2014b; Ota et al., 2015). In the current review, we have
summarized the currently available data and discussed potential
clinical importance of anti-EGFR immune responses and EGFR-
mediated immune regulation.
CELLULAR IMMUNE RESPONSES TO
WILD TYPE EGFR
Cellular immune responses specific to wild-type EGFR have
been studied in patients with several types of cancer, including
NCSLC and head and neck squamous cell carcinoma (HNSCC).
For example, Shomura et al. (2004a) identified three HLA-A24-
restricted epitopes derived from wild-type EGFR at positions
54–62, 124–132, and 800–809, which were able to induce both
specific cellular and humoral immune responses in most of
NCSLC patients. In addition, the same group also reported two
HLA-A2-restricted epitopes derived from wild-type EGFR at
positions 479–488 and 1138–1147, both of which were able to
induce both specific cellular and humoral immune responses in
NCSLC patients (Shomura et al., 2004b). Interestingly, Schuler
et al. (2011) demonstrated that the frequency of cytotoxic T
cell (CTL) specific to these two HLA-A2-restricted epitopes
in peripheral blood of HNSCC patients correlated significantly
with EGFR expression in tumor tissues. HNSCC patients with
elevated EGFR expression had a significantly higher frequency
of EGFR-specific CTL than those with lower EGFR expression
or normal individuals. This finding suggested that EGFR
expressed on tumor cells might induce a specific cellular immune
response in vivo. We have used one of the HLA-A24-restricted
epitopes, EGFR800−809, as a candidate peptide for personalized
peptide vaccination, in which vaccine antigens are selected
and administered based on the pre-existing host immunity
before vaccination (Sasada et al., 2014). Recent clinical trials of
personalized peptide vaccination have demonstrated significantly
prolonged overall survival in patients with advanced cancers,
including prostate and bladder cancer, through induction of
antigen-specific T cells (Sasada et al., 2014; Noguchi et al., 2016;
Yoshimura et al., 2016).
Andrade Filho et al. identified another immunogenic HLA-
A2-restricted epitope, EGFR853−861, derived from wild-type
EGFR, and showed that EGFR853−861-specific T cells were
increased in the peripheral circulation of HNSCC patients
(Andrade Filho et al., 2010). Notably, they demonstrated that
recognition of HNSCC cells by EGFR853−861-specific T cells
was enhanced by incubation of tumor cells with the EGFR-
blocking monoclonal antibody (mAb) cetuximab, which might
facilitate antigen presentation through enhanced internalization
and proteasomal degradation of EGFR (Vincenzi et al., 2008)
and STAT-1-induced HLA class I upregulation (Srivastava et al.,
2015). These results suggest that EGFR-specific T cells in
cetuximab-treated HNSCC patients may contribute to anti-
tumor activity relevant to clinical responses. In addition,
they showed that cetuximab-activated NK cells promote DC
maturation, which increased EGFR-specific T cell responses
through enhanced cross-presentation of EGFR for T cell priming
(Srivastava et al., 2013). It may thus be possible that EGFR-
specific T cell responses would be useful as a potential biomarker
to monitor effects of cetuximab treatment in HNSCC patients.
Kumai et al. (2013) identified a novel promiscuous helper T
cell epitope, EGFR875−889, which is restricted by several different
HLA class II types, including HLA-DR4, HLA-DR15, and HLA-
DR53. EGFR875−889-specific CD4 T cells can be detected in
the peripheral blood of HNSCC patients, and was shown to
react against tumor cells expressing EGFR as well as other
ErbB/HER family members (HER-2, HER-3) and c-kit, which
have homologous peptide sequences. Interestingly, treatment of
tumor cells with EGFR tyrosine kinase inhibitors (EGFR-TKI)
was shown to upregulate HLA-DR expression on tumor cells and
enhance recognition by EGFR875−889-specific CD4 T cells.
Although direct therapeutic targeting of EGFR by the blocking
mAbs and specific inhibitors have been extensively studied,
there have been limited information on therapeutic application
of EGFR-specific T cell responses. Clinical trials are warranted
to show a feasibility of immunotherapeutic approach targeting
EGFR.
CELLULAR IMMUNE RESPONSES TO
MUTATED EGFR
Since mutated genes are recognized as foreign by the host
immune system, they might elicit stronger immune responses
and can be an appropriate target for cancer immunotherapy
(Schumacher and Schreiber, 2015). Several studies have been
reported regarding immune responses to tumor-specific EGFR
mutations, such as EGFRvIII in GBM and EGFR T790M in
NSCLC.
EGFR variant III is a tumor specific mutation that is widely
expressed in GBM and other neoplasms (Sampson et al., 2008;
Guo et al., 2015). This mutation encodes a constitutively
active tyrosine kinase that is reported to be associated with
tumorigenicity and cellular resistance to chemotherapeutic
agents or radiation. EGFRvIII is an in-frame deletion mutation
that introduces a novel glycine residue at the fusion junction
between distant parts of the wild-type EGFR sequence. This
sequence rearrangement has been reported to create a tumor-
specific neoepitope that elicit specific cellular and humoral
immune responses in GBM patients (Sampson et al., 2008;
Guo et al., 2015). As immunotherapeutic approach to GBM
that express EGFRvIII, an investigational vaccine (rindopepimut)
consisting of the unique EGFRvIII peptide sequence conjugated
to keyhole limpet hemocyanin (KLH) has been tested in
clinical trials. Multiple phase I and phase II clinical trials
demonstrated that the vaccine generated specific cellular and
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humoral immune responses and tended to show clinical benefits
in GBM patients with EGFRvIII mutation (Sampson et al.,
2008, 2010; Schuster et al., 2015). Following these promising
results, a randomized, double-blind, controlled phase III study
named ACT IV, in which rindopepimut plus GM-CSF or KLH
alone (control) were administered in combination with standard
of care temozolomide, was conducted in newly diagnosed
EGFRvIII-positive GBM patients. However, disappointedly the
ACT IV study was discontinued in March 2016 based on the
recommendation of the independent Data Safety and Monitoring
Board that the study was unlikely to meet its primary overall
survival endpoint in patients with minimal residual disease
(according to the press release of Celldex Therapeutics, Inc.).
We and others have reported immune responses to another
EGFR mutation, EGFR T790M, which occurs in around 60% of
NSCLC patients with acquired resistance to EGFR-TKI, such as
gefitinib and erlotinib (Yamada et al., 2013; Ofuji et al., 2015).
Whereas most NSCLC patients with EGFR activating mutations
found in the exons 19 or 21 of the EGFR gene transiently benefit
from treatment with EGFR-TKI, almost all individuals eventually
develop resistance to these drugs over time (median of 6–
12 months). The secondary T790M mutation has been reported
to be associated with resistance to EGFR-TKI by negating the
hypersensitivity of activating EGFR mutations (Tan et al., 2015).
We have identified two novel HLA-A2-restricted T cell epitopes
(MQLMPFGCLL and LIMQLMPFGCL) containing the mutated
methionine residue of the EGFR T790M as potential targets for
EGFR-TKI-resistant patients (Yamada et al., 2013). The identified
EGFR T790M-derived epitopes induced much stronger T cell
responses, compared to the epitopes derived from wild-type
EGFR. In addition, Ofuji et al. (2015) also reported another HLA-
A2-restricted T cell epitope (IMQLMPFGC) derived from EGFR
T790M. Of note, a negative correlation between the immune
responses to the EGFR-T790M-derived epitopes and the presence
of EGFR-T790M mutation was observed in NSCLC patients
(Yamada et al., 2013). It may thus be possible that EGFR T790M-
specific immune responses might prevent the emergence of
tumor cell variants with the T790M mutation in NSCLC patients
during EGFR-TKI treatment. Given high immunogenicity in
human T cells, the identified T cell epitopes might provide a novel
immunotherapeutic approach for prevention and/or treatment of
EGFR-TKI resistance associated with the EGFR T790M mutation
in NSCLC patients (Figure 1). Clinical trials are recommended
for development of immunotherapy targeting EGFR T790M.
HUMORAL IMMUNE RESPONSE TO
EGFR
Humoral immune responses to HER2 have been extensively
studied, and their clinical importance in a variety of cancers
has been reported (Chapman et al., 2008; Knutson et al.,
2016; Tabuchi et al., 2016). However, there have been limited
information on humoral immune response to EGFR in cancer.
Pandey et al. (2015) showed that higher antibody levels specific
to wild-type EGFR or EGFRvIII, which were associated with
immunoglobulin allotypes, were related to improved overall
FIGURE 1 | Immunotherapy with EGFR T790M-derived peptides
against NSCLC patients with EGFR T790M mutation. EGFR
T790M-derived immunogenic T cell epitopes might provide a novel
immunotherapeutic approach for prevention and/or treatment of EGFR-TKI
resistance associated with the EGFR T790M mutation in NSCLC patients.
survival in GBM patients. Olsen et al. (2013) reported a negative
correlation between autoantibody levels against EGFR in serum
and disease free survival in breast cancer patients with relapse or
death. These results suggest that stronger immune responses to
EGFR might be related to better prognosis in cancer, but further
studies remain to elucidate the clinical importance of humoral
immune response to EGFR in a variety of cancers.
Humoral immune responses to EGFR in NSCLC patients have
not been well studied. Therefore, we investigated the clinical
significance of humoral immune responses to EGFR-derived
peptides in NSCLC patients receiving EGFR-TKI, gefitinib
(Azuma et al., 2014a). Gefitinib has been known to be especially
effective in patients with activating EGFR mutations, most of
which (about 90%) occur in the tyrosine kinase domain of
EGFR located in the exon 19 (deletion such as delE746-A750)
or exon 21 (L858R point mutation) (Tan et al., 2015). We
measured plasma IgG titers to each of 60 different EGFR-
derived 20-mer peptides spanning the entire sequence of
EGFR in 42 NSCLC patients receiving gefitinib (Azuma et al.,
2014a). We reported that IgG titers against three EGFR-derived
peptides, EGFR481−500, EGFR721−740, and EGFR741−760, were
significantly higher in patients with the exon 21 mutation.
On the other hand, IgG titers against two EGFR-derived
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peptides, EGFR841−860 and EGFR1001−1020, were significantly
lower and higher, respectively, in patients with deletion in the
exon 19. These results suggest that EGFR mutations may be
associated with humoral responses to EGFR in NSCLC patients.
In addition, multivariate Cox regression analysis showed that
IgG responses to EGFR41−60, EGFR61−80, and EGFR481−500
were significantly prognostic for progression-free survival
independent of other clinicopathological characteristics, whereas
those to the EGFR41−60 and EGFR481−500 were significantly
prognostic for overall survival. Although further study is needed
to clarify the mechanisms of the increased IgG responses to
these sequences, our results may provide new insight for better
understanding of humoral responses to EGFR in NSCLC patients.
TARGETING OF EGFR WITH CHIMERIC
ANTIGEN RECEPTOR (CAR)-MODIFIED
T CELLS
Chimeric antigen receptor is a synthetic molecule designed to
redirect T cells to specific antigens expressed on surface of tumor
cells. Adoptive immunotherapy with CAR-engineered T cells
show long-term durable remission in B cell malignancies (Maude
et al., 2014), but not in solid tumors. Application of this approach
to solid tumors requires the identification and selection of target
antigens with limited expression on surface of normal cells. Since
EGFRvIII mutation that is widely expressed in GBM and other
neoplasms has a neoepitope resulting from an in-frame deletion
of a part of the extracellular domain of EGFR (Sampson et al.,
2008; Guo et al., 2015), it might be an excellent target for CAR-
engineered T cell therapy. Recently, Johnson et al. (2015) showed
potential efficacy of EGFRvIII-targeted CAR-engineered T cells in
in vitro cell culture system and in vivo mouse models. Similarly,
Han et al. (2015) also demonstrated the feasibility of EGFRvIII-
targeted CAR-engineered NK cells. A phase I clinical trial of
EGFRvIII-targeted CAR-engineered T cells is currently underway
for patients with EGFRvIII-positive recurrent GBM.
In contrast, wild-type EGFR has been thought inappropriate
for a target molecule of CAR-engineered T cells due to
possible deleterious recognition of normal cells, because EGFR
is expressed not only tumor cells but also normal cells at
physiological levels. However, recent reports demonstrated that
affinity of single-chain variable fragment (scFv) of CAR can be
tuned to distinguish tumor cells from normal cells based on
the disparate density of EGFR expression (Caruso et al., 2015;
Liu et al., 2015). Additional studies are required for further
pre-clinical evaluation of this novel approach.
MODULATION OF PD-L1 EXPRESSION
BY EGFR-MEDIATED SIGNALING
Blockade of immune checkpoints with mAbs has recently
emerged as a new therapeutic tool in oncology (Postow
et al., 2015; Topalian et al., 2016). Programmed cell death 1
(PD1), a type 1 transmembrane protein of the immunoglobulin
superfamily, is one of the immune checkpoints expressed on the
surface of several types of immune cells, including T cells, B cells,
and NK cells. Its ligand, PD-L1, is frequently overexpressed in
many types of human cancer. The binding of PD-L1 to PD1
induces apoptosis or exhaustion in activated T cells, and blockade
of this interaction has been shown to enhance the antitumor
activity of T cells. Recent clinical trials have demonstrated that
inhibition of the PD-L1–PD1 interaction with the blocking
mAbs, such as nivolumab and pembrolizumab, show promising
antitumor effects in patients with various malignancies including
NSCLC (Postow et al., 2015; Topalian et al., 2016).
PD-L1 expression has been reported to be driven by
some of oncogenic pathways (Topalian et al., 2016). Several
studies have reported the association between PD-L1 expression
and mutant EGFR mediated signaling. Akbay et al. (2013)
showed that mutant EGFR signaling drives increased PD-
L1 expression and that blockade of PD1 improved survival
of mice in EGFR-driven murine lung tumors. They also
demonstrated that forced expression of mutant EGFR induced
PD-L1 expression in human bronchial epithelial cell lines, and
that EGFR inhibitors reduced PD-L1 expression in NSCLC
cell lines with activating EGFR mutations. Similarly, we and
others showed that EGFR activation by EGF stimulation or
mutant EGFR upregulated PD-L1 expression by activating
PI3K-AKT and MEK-ERK signaling pathways in NSCLC cells
(Azuma et al., 2014b; Chen et al., 2015; Ota et al., 2015).
In addition, Lastwika et al. (2016) demonstrated that active
AKT/mTOR signaling mediated by activating EGFR mutation
or EGF treatment induced PD-L1 expression in NSCLC cell
lines in vitro and in mouse models in vivo. These results clearly
FIGURE 2 | Modulation of PD-L1 expression by EGFR-mediated
signaling. PD-L1 expression is induced through activation of EGFR signaling
pathway mediated by activating EGFR mutations or EGF treatment.
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indicate that EGFR downstream signaling pathway mediated by
activating EGFR mutations or EGF treatment drives increased
PD-L1 expression (Figure 2).
In contrast to the studies performed using cell lines and/or
in vivo mouse models, the correlation between mutant EGFR
status and PD-L1 expression in tumor tissues in NSCLC patients
seems to be controversial. We examined the association between
PD-L1 expression in surgically resected tumor tissues and
other clinicopathologic characteristics in 164 NSCLC patients
(Azuma et al., 2014b). Multivariate analysis demonstrated that
presence of EGFR mutations and adenocarcinoma histology
were significantly associated with increased PD-L1 expression
independently of other factors. Similarly, D’Incecco et al. (2015)
also showed that PD-L1 positivity was significantly associated
with adenocarcinoma histology and the presence of EGFR
mutations in a cohort of 125 NSCLC patients. Tang et al.
(2015) also demonstrated that PD-L1 expression tended to be
associated with activating EGFR mutations in 145 advanced
lung adenocarcinoma. Interestingly, patients harboring EGFR
mutations with higher PD-L1 expression showed more sensitivity
to EGFR-TKI probably because of PD-L1 downregulation
induced by the EGFR inhibition (D’Incecco et al., 2015; Lin et al.,
2015). In contrast, Yang et al. (2014) observed no significant
correlation between PD-L1 expression and EGFR, KRAS, BRAF,
or ALK mutations in 163 surgically resected stage I lung
adenocarcinoma patients. Similarly, Cooper et al. (2015) found
no association between PD-L1 expression and EGFR or KRAS
mutation status in 678 stage I-III NSCLC patients. Based on these
reported studies, the relationship between mutant EGFR status
and PD-L1 expression in tumor tissues is inconclusive.
There may be several reasons for such discrepancy. One
possible reason may be the heterogeneity of histological cell
types (adenocarcinoma vs. squamous cell carcinoma) and/or
disease stages (early vs. advanced) in the patients examined
(Topalian et al., 2016). Another possible reason may be related
to the different protocols and materials (mAbs) employed
for immunohistochemical staining (Topalian et al., 2016). In
addition, PD-L1 expression has been reported to be driven by not
only oncogenic signaling but also adaptive immune responses,
such as IFN-γ-mediated stimulation (Topalian et al., 2016).
Therefore, more precise and detailed studies are warranted to
clarify relationship between mutant EGFR status and PD-L1
expression in tumor tissues. Of note, it has recently been reported
that NSCLC patients with activating EGFR mutations show lower
objective responsive rates to PD-1/PD-L1 inhibitors (Gainor
et al., 2016; Melosky et al., 2016), suggesting the possibility
that mutant EGFR status cannot be a satisfactory biomarker for
assessing the effects of PD-1/PD-L1 blockade in NSCLC.
CONCLUSION
Several lines of recent evidence suggest that immune responses
to EGFR might be useful as a marker and/or target for
cancer therapy. In particular, since highly immunogenic T cell
epitopes have been identified from wild-type and mutant EGFR,
their clinical application as a novel immunotherapy might be
promising for treatment of EGFR-associated cancer. In addition,
recent studies suggest the potential roles of EGFR-mediated
signaling in regulation of expression of the checkpoint molecule,
PD-L1, in tumor cells, although the correlation between mutant
EGFR status and PD-L1 expression in tumor tissues has
been inconclusive. Considering notable clinical significance of
immune checkpoint blockers, more precise and detailed studies
are recommended to clarify the relationship between EGFR status
and immune checkpoint expression.
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